Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ALEC | US
0.06
1.15%
Healthcare
Biotechnology
30/06/2024
30/08/2024
5.28
5.24
5.30
5.16
Alector Inc. a clinical stage biopharmaceutical company develops therapies for the treatment of neurodegeneration diseases. Its products include AL001 an immune activity in the brain with genetic links to multiple neurodegenerative disorders which is in Phase III clinical trial for the treatment of frontotemporal dementia Alzheimer's Parkinson's and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases including Alzheimer's and Parkinson's diseases. The company also offers AL002 a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003 which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A a risk gene for Alzheimer's disease. Alector Inc. has a collaboration agreement with Adimab LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies such as AL001 AL002 and AL101 to treat neurodegenerative diseases. Alector Inc. was founded in 2013 and is headquartered in South San Francisco California.
View LessLow Market Beta (-0.4 to 0.8)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.8%1 month
55.7%3 months
63.4%6 months
60.0%-
526.32
3.43
-
-
-8.40
0.90
-
-181.60M
513.86M
513.86M
-
-302.37
-86.30
-73.20
-92.64
6.89
6.01
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.37
Range1M
1.59
Range3M
2.67
Rel. volume
0.91
Price X volume
2.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pharming Group N.V. | PHAR | Biotechnology | 7.69 | 558.03M | -1.16% | n/a | 63.43% |
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 12 | 557.32M | -0.41% | 62.79 | 0.75% |
PureTech Health plc | PRTC | Biotechnology | 23 | 550.43M | 1.46% | n/a | 5.50% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 10.5 | 546.30M | -4.28% | n/a | 0.43% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 7.62 | 536.23M | -0.78% | n/a | 0.00% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 8.55 | 533.53M | -2.17% | n/a | 0.00% |
Sage Therapeutics Inc | SAGE | Biotechnology | 8.43 | 514.65M | 4.20% | n/a | 0.22% |
Anavex Life Sciences Corp | AVXL | Biotechnology | 6.02 | 510.47M | 0.84% | n/a | 0.00% |
Valneva SE | VALN | Biotechnology | 7.32 | 509.30M | -0.27% | n/a | 0.00% |
LRMR | LRMR | Biotechnology | 7.91 | 504.71M | -1.74% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 50.52 | 0.00% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 0.00% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.84 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.51 | -621.78% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 18.53 | 314.66M | -0.70% | 8.90 | 25.57% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 15.53 | 251.70M | 1.70% | 11.69 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.20 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 15.04 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -8.40 | 1.02 | Cheaper |
Ent. to Revenue | 0.90 | 3,693.42 | Cheaper |
PE Ratio | - | 40.05 | - |
Price to Book | 3.43 | 14.24 | Cheaper |
Dividend Yield | - | 2.25 | - |
Std. Deviation (3M) | 63.42 | 77.16 | Par |
Debt to Equity | - | -5.69 | - |
Debt to Assets | - | 0.24 | - |
Market Cap | 513.86M | 4.06B | Emerging |